Personalized circulating tumor DNA (ctDNA) during neoadjuvant therapy (NAT) to predict response in patients (pts) with breast cancer (BC) Published Date June 9, 2023 Expand Fullscreen Exit Fullscreen Download PDF Expand Fullscreen